Groß, RüdigerRüdigerGroßLívia Mesquita, Dias LoiolaDias LoiolaLívia MesquitaIssmail, LeilaLeilaIssmailUhlig, NadjaNadjaUhligEberlein, ValentinaValentinaEberleinConzelmann, CarinaCarinaConzelmannOlari, Lia-RalucaLia-RalucaOlariRauch, LenaLenaRauchLawrenz, JanJanLawrenzWeil, TatjanaTatjanaWeilMüller, Janis A.Janis A.MüllerCardoso, Mateus BorbaMateus BorbaCardosoGilg, AndreaAndreaGilgLarsson, OliviaOliviaLarssonHöglund, UrbanUrbanHöglundAxberg Pålsson, SandraSandraAxberg PålssonTvilum, Anna SelchAnna SelchTvilumLøvschall, Anna SelchAnna SelchLøvschallKristensen, Maria M.Maria M.KristensenSpetz, Anna-LenaAnna-LenaSpetzHontonnou, FortuneFortuneHontonnouGalloux, MarieMarieGallouxZelikin, Alexander N.Alexander N.ZelikinGrunwald, ThomasThomasGrunwaldMünch, JanJanMünch2023-01-192023-01-192022https://publica.fraunhofer.de/handle/publica/41797710.1002/advs.202201378Inhibitors of viral cell entry based on poly(styrene sulfonate) and its core–shell nanoformulations based on gold nanoparticles are investigated against a panel of viruses, including clinical isolates of SARS-CoV-2. Macromolecular inhibitors are shown to exhibit the highly sought-after broad-spectrum antiviral activity, which covers most analyzed enveloped viruses and all of the variants of concern for SARS-CoV-2 tested. The inhibitory activity is quantified in vitro in appropriate cell culture models and for respiratory viral pathogens (respiratory syncytial virus and SARS-CoV-2) in mice. Results of this study comprise a significant step along the translational path of macromolecular inhibitors of virus cell entry, specifically against enveloped respiratory viruses.enBroad-spectrum antiviralsEntry inhibitorsIn vivoMacromoleculesPolyanionsRespiratory syncytial virus (RSV)SARS-CoV-2journal article